A study to evaluate the first dose of gentamicin needed to achieve a peak plasma concentration of 30 mg/l in patients hospitalized for severe sepsis

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 35, Issue 7, 2016, Pages 1187-1193

  Allou, N ^a   Charifou, Y ^a   Augustin, P ^b   Galas, T ^a   Valance, D ^a   Corradi, L ^a   Martinet, O ^a   Vandroux, D ^a   Allyn, J ^a  

^a Groupe Hospitalier Felix Guyon   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GENTAMICIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL TRIAL; COHORT ANALYSIS; DRUG BLOOD LEVEL; EVALUATION STUDY; FEMALE; HOSPITAL PATIENT; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SEPTIC SHOCK; COMORBIDITY; DRUG MONITORING; HOSPITALIZATION; MIDDLE AGED; MORTALITY; PROGNOSIS; RISK FACTOR; SEPSIS; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; COMORBIDITY; DRUG MONITORING; FEMALE; GENTAMICINS; HOSPITALIZATION; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; SEPSIS; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC; TREATMENT OUTCOME;

EID: 84965060047     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-016-2652-6     Document Type: Article

References (17)

1. Agence française de sécurité sanitaire des produits de santé (2012) Update on good use of injectable aminoglycosides, gentamycin, tobramycin, netilmycin, amikacin. Pharmacological properties, indications, dosage, and mode of administration, treatment monitoring. Med Mal Infect 42:301–308
2. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228
3. Moore RD, Lietman PS, Smith CR (1987) Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 155:93–99
4. EUCAST. European Committee on Antimicrobial Susceptibility Testing. www.eucast.org/. 2015
5. Roger C, Nucci B, Louart B, Friggeri A, Knani H, Evrard A, Lavigne JP, Allaouchiche B, Lefrant JY, Roberts JA, Muller L (2016) Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis. J Antimicrob Chemother 71:208–212
6. Allou N, Allyn J, Levy Y, Bouteau A, Caujolle M, Delmas B, Valance D, Brulliard C, Martinet O, Vandroux D, Montravers P, Augustin P (2016) Assessment of the National French recommendations regarding the dosing regimen of 8 mg/kg of gentamicin in patients hospitalized in intensive care unit. Anaesth Crit Care Pain Med [In press]
7. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370:1453–1457
8. Blackburn LM, Tverdek FP, Hernandez M, Bruno JJ (2015) First-dose pharmacokinetics of aminoglycosides in critically ill haematological malignancy patients. Int J Antimicrob Agents 45:46–53
9. Duszynska W, Taccone FS, Hurkacz M, Kowalska-Krochmal B, Wiela-Hojenska A, Kubler A (2013) Therapeutic drug monitoring of amikacin in septic patients. Crit Care 17:R165
10. Traynor AM, Nafziger AN, Bertino JS Jr (1995) Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother 39:545–548
11. Roger C, Nucci B, Molinari N, Bastide S, Saissi G, Pradel G, Barbar S, Aubert C, Lloret S, Elotmani L, Polge A, Lefrant JY, Roberts JA, Muller L (2015) Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations. Int J Antimicrob Agents 46:21–27
12. Montravers P, Dufour G, Guglielminotti J, Desmard M, Muller C, Houissa H, Allou N, Marmuse JP, Augustin P (2015) Dynamic changes of microbial flora and therapeutic consequences in persistent peritonitis. Crit Care 2(19):70
13. Bertino JS Jr, Booker LA, Franck PA, Jenkins PL, Franck KR, Nafziger AN (1993) Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 167:173–179
14. Maller R, Ahrne H, Holmen C, Lausen I, Nilsson LE, Smedjegard J (1993) Once- versus twice-daily amikacin regimen: efficacy and safety in systemic gram-negative infections. Scandinavian Amikacin Once Daily Study Group. J Antimicrob Chemother 31:939–948
15. Oliveira JF, Silva CA, Barbieri CD, Oliveira GM, Zanetta DM, Burdmann EA (2009) Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units. Antimicrob Agents Chemother 53:2887–2891
16. Taccone FS, Laterre PF, Spapen H, Dugernier T, Delattre I, Layeux B, De Backer D, Wittebole X, Wallemacq P, Vincent JL, Jacobs F (2010) Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care 14:R53
17. Schneider AG, Thorpe C, Dellbridge K, Matalanis G, Bellomo R (2013) Electronic bed weighing vs daily fluid balance changes after cardiac surgery. J Crit Care 28(1113):e1–e5